Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 31,362 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Clarithromycin Mechanisms in Hypersomnia Syndromes

NCT04026958
Conditions
Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy
Interventions
Clarithromycin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Soft Tissue Sarcoma
Interventions
Atezolizumab, Doxorubicin Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab and rHuPH20, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of Lasmiditan in Healthy Participants

NCT03252015
Conditions
Healthy
Interventions
Probe Drug Cocktail, Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

The SIM-PLICITY Study: The SIMulation Project - LIstening & Intervention in Pediatric obeSITY

NCT02946515
Conditions
Childhood Obesity
Interventions
Educational Intervention, Wait List Control
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bloomington, Minnesota
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 9 more
Conditions
Healthy Volunteers
Interventions
Irafamdastat
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Conditions
Solid Tumor
Interventions
BHV-1530, Cemiplimab
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more
Conditions
HIV Infections, Osteopenia, Osteoporosis
Interventions
Zoledronate, Zoledronate placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Conditions
Healthy Volunteer
Interventions
ABBV-701, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 3 more
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Conditions
Cancer, Breast, Cancer, Uterus, Cancer, Ovary, Obesity, Activity, Motor, Diet, Healthy
Interventions
With Love, Grandma ("Con Cariño, Abuelita")
Behavioral
Lead sponsor
University of Miami Sylvester Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo, Fingolimod
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional

mHealth Family Self-Management

NCT03533049
Conditions
Transplantation, Pediatric ALL
Interventions
myFAMI
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Tobacco Use Disorder, Medication Adherence
Interventions
Varenicline
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Recruiting Not applicable Interventional Accepts healthy volunteers

A Smoke-Free Home Intervention in Tribal Communities

NCT06583148
Conditions
Tobacco-Related Carcinoma
Interventions
Best Practice, Smoking Cessation Intervention, Survey Administration
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee
Completed Not applicable Interventional Results available

Abbott Next Generation Drug Eluting Stent 48mm Study

NCT04282148
Conditions
Coronary Artery Disease
Interventions
ABT NG DES 48 EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Birmingham, Alabama • Beverly Hills, California + 17 more
Completed Phase 2 Interventional

Text to Move (TTM)Study

NCT01569243
Conditions
Type 2 Diabetes Mellitus
Interventions
Text messages, Usual care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Healthy
Interventions
Darunavir (DRV), Cobicistat (COBI), Emtricitabine (FTC), Tenofovir Alafenamide (TAF)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona